BridgeBio Inc.

About BridgeBio Inc.

BridgeBio is a biopharmaceutical company that pioneered a 'moneyball for biotech' approach in 2015, pooling early-stage research projects from academia under one financial umbrella to reduce risk and accelerate innovation in rare disease therapeutics. The company builds bridges to groundbreaking advancements and develops life-changing medicines for patients with unmet medical needs as quickly as possible. BridgeBio operates through independent sister companies, including GondolaBio, a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases that secured $300M in private financing in 2024. The company emphasizes a science-driven model led by small teams of experts and values curiosity, experimentation, and the ethical use of AI to improve the speed and quality of drug discovery and development.